Vertex
Bookmark
ShareCopied to clipboardVertex is a company. It is a public company in Boston, the United States. It was founded in 1989 and its current CEO is Reshma Kewalramani. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Boston
- country: United States
- employees: 6,100 people
- revenues: 11B $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1989
- CEO: Reshma Kewalramani
- CEO approval: 48 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Vertex:
Dataset of stocks from Vertex:
Vertex is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Boston and 3,456,808 companies in our database.
Talking Points
- Vertex Pharmaceuticals | Home
- Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- The official Twitter channel for Vertex Pharmaceuticals. https://t.co/ILl5NijkRL
- The Science of Possibility | Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease.
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.